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1 |  INTRODUCTION
Congenital hypogonadotropic hypogonadism (HH) has an 
association to hereditary causes in 30%-50% of affected sub-
jects. TACR3 is one of the genes with a higher number of 
known mutations. The authors present a new association of 
two heterozygous TACR3 mutations, found in three siblings 
diagnosed with normosmic HH.
Puberty is a specialized phase in human development 
characterized by a gradual increase in the hypothalamo-pitu-
itary-gonadal axis’ activity during the second decade of life and 
which lasts from two to five years.1 The hallmark of puberty 
is the beginning of a pulsatile secretion of gonadotropin-re-
leasing hormone (GnRH) by hypothalamus, which triggers 
the release of the gonadotropin luteinizing hormone (LH) and 
follicle-stimulating hormone (FSH) from the pituitary gland.2 
These hormones act in gonadal tissue to drive both sex hor-
mone secretion and gametogenesis, therefore inducing matu-
ration of secondary sexual features and reproductive system.1,2
In hypogonadotropic hypogonadism (HH), there is a 
failure of puberty onset due to insufficient gonadotropin re-
lease for unknown reasons. This results in the incapacity to 
develop secondary sexual characteristics and a mature repro-
ductive system at 13  years of age in girls and 14  years of 
age in boys.1,3 Traditionally, HH is divided into two catego-
ries: Kallmann syndrome (KS) and normosmic HH (nHH), 
based on the absence or presence of normal sense of smell, 
respectively.1,3-5
Hypogonadotropic hypogonadism can be inherited or ac-
quired. Currently, known genetic defects account for about 
30%-50% of all HH cases with around 50 mutated genes 
already associated.1,3,5 Loss-of-function TACR3 mutations 
have been described as causative of congenital HH, pointing 
out the key role of this gene in the regulation of the human 
gonodotrope axis.6
2 |  CASE REPORT
In a family originated from Lisbon (Portugal), three of four 
children of nonconsanguineous parents were found to have 
nHH (Figure 1).
The index case was a young man (Subject III-1) who was 
referred at 16 years of age because pubertal development had 
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The authors present a new association of two heterozygous TACR3 mutations 
(p.Arg230His and p.Trp275*) responsible for a clinical trait of normosmic congeni-
tal hypogonadotropic hypogonadism in a family.
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not occurred. He had typical signs of complete hypogonad-
ism, with small intrascrotal testes (2-3 ml), spar pubic hair 
(P1-2), and a small phallus. His height was 161.5 cm (Z-score 
−1.57), his weight 61.9 kg (z-score 0.08), and his bone age 
12.5 years. His body proportions were normal. He had a nor-
mal sense of smell, and no renal or craniofacial abnormalities.
His affected sisters (Subjects III-3 and III-4) were evalu-
ated at 14 and 13 years old, respectively, and also presented 
complete hypogonadism and a normal sense of smell on 
olfactometry. They presented with no breast development, no 
pubic hair, and no menarche. Subjects III-3 and III-4 heights 
were 153 cm (z-score −1.19) and 144.2 cm (z-score −2.04), 
respectively, their weights were 51.3  kg (z-score 0.53) and 
43.1 kg (z-score 0.15), and their bone ages 12.5 and 10 years. 
Their developmental background was normal. There was no 
history for eating disorder, chronic illness, or head trauma.
The unaffected sister (Subject III-2) had normal pubertal 
development with spontaneous regular menses at 13  years 
old.
The onset of their mother's (Subject II-1) menarche was 
at 15 years old. She reported having had spontaneous regu-
lar menses, unassisted conception, and normal pregnancies. 
Their father (Subject II-2) stated that he had a normal puber-
tal development at 13 years old.
All the unaffected family members presented a normal 
sense of smell.
Hormone assays revealed very low plasma testosterone 
levels in the affected brother and an undetectable plasma es-
tradiol level in the affected sisters (Table 1). Very low plasma 
gonadotropin levels were detected in all the subjects.
All of them had normal function of the anterior pituitary, 
thyroid, and adrenal glands, along with normal levels of ferri-
tin and serum insulin-like growth factor I. Subjects III-1 and 
III-3 presented normal findings on MRI of the pituitary and 
olfactory bulbs, and subject III-4 is still awaiting for the com-
pletion of her study. The affected male presented an apulsa-
tile result in endogenous basal LH pulsatility study.
Pelvic sonography revealed an absence of uterus and the 
presence of two small ovaries (right, 13 mm; left 22 mm), 
with no visible follicles, in subject III-3. In subject III-4, it 
showed a small uterus (22 mm) and two small ovaries (right, 
19 mm; left 13.7 mm), with no visible follicles.
Karyotypes were normal in index case subject III-1 
(46,XY) and subjects III-3 and III-4 (46,XX).
A diagnosis of nHH was established based on the ab-
sence of spontaneous puberty and hypogonadal sex steroid 
F I G U R E  1  Family Pedigree. Solid symbols indicate affected subjects (III-1, III-3, III-4), and open symbols indicate subjects with no 
mutations. The symbols ⋄ and † indicate unaffected heterozygotes. - ⋄ - refers to the mutation c.824G>A (p.Trp275*) inherited from the subject 
II-2 and † to the mutation c.689G > A (p.Arg230His) from subject II-1. Circles represent female family members and squares male family 
members
T A B L E  1  Data for affected family members
Subject III-1 III-3 III-4
Age (y) 16 14 13
Sense of smell Normal Normal Normal
Breasts (Tanner stage) I I I
Pubic hair (Tanner stage) I-II I II
External genitalia (Tanner 
stage)
I I I
Penis length (cm) 4 - -
Testicular volume (mL) 2-3 - -
LH (mIU/mL) 0.2 <0.1 <0.09
FSH (mIU/mL) 0.6 0.7 0.29
Estradiol (pg/mL) ND <10 <10
Testosterone (ng/mL) 0.14 0.15 ND
Prolactin (ng/mL) 3.42 4.3 ND
IGF-1 (ng/mL) 272 144 144
Bone age (y) 12.6 12.5 10
MRI head Normal Normal ND
LH pulsatility Apulsatile ND ND
Note: Normal ranges for the hormones listed are as follows: for men: FSH, 0.95-
11.95 mIU/mL; LH, 0.57-12.09 mIU/mL; testosterone, 3-12 ng/mL; prolactin, 
4.2-23.04 ng/mL; and IGF-1, 163-584 ng/mL for Tanner stage I; for women 
(in early follicular phase): FSH, 3.03-8.08 mIU/mL; LH, 1.8-11.78 mIU/mL; 
estradiol, 21-251 pg/mL; prolactin, 11-23 ng/mL; and IGF-1, 71-394 ng/mL for 
Tanner stage I. ND denotes not done.
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levels (testosterone ≤ 100 ng/dL; oestradiol ≤ 20 pg/mL) at 
a normal pubertal age in all three subjects in the setting of 
inappropriately low gonadotropin levels without associated 
anosmia and no evidence of a mass lesion on the imaging 
of hypothalamic pituitary region. Normal basal levels of thy-
roid-stimulating hormone, prolactin, and adrenal hormones 
supported the diagnosis.
Genetic study in the index case revealed two heterozy-
gous mutations on TACR3 gene: c.824G>A (p.Trp275*), 
previously described as pathogenic, and c. 689G>A (p. 
Arg230His), with conflicting evidence about its pathoge-
nicity. The TACR3 gene is responsible for autosomal re-
cessive hypogonadotropic hypogonadism type 11, with or 
without anosmia. The studies to the parents confirmed the 
compound heterozygosity, and the studies performed to the 
siblings confirmed segregation of the genotype with the 
phenotype: Case III-3 and III-4 shared the two TACR vari-
ants with index case. These results confirmed the pathoge-
nicity of the second variant (p. Arg230His) and the clinical 
diagnosis.
The index case received testosterone enanthate treatment 
at 16.5  years for 3  months, with adequate virilization re-
sponse. Three months later, the testis volume was 3-4 mL, 
so gonadarche was induced with human chorionic gonad-
otrophin starting from a dose of 1500 UI twice a week for 
6 months. During puberty induction, testis volume increased 
to 6 mL and a progressive rise of testosterone and inhibin B 
was observed. During the next four years, he progressively 
gained testicular volume (testes 12-15 mL) and penis length 
(9 cm stretched length) in a spontaneous manner. At 21 years 
old, he presented a Tanner stage of P5G4A4.
Subject III-3 started continuous transdermal low-dose 
conjugated estrogen with a confirmed onset of breast growth. 
After 8 months of treatment, control pelvic sonography re-
vealed an uterus (65 × 15 mm, 7 × 15 mm) with centered en-
dometrium and the presence of two ovaries (right 24.3 × 15 
mm; left 15 × 16.5 mm) with small follicles.
Subject III-4 will start continuous transdermal low-dose 
conjugated estrogen.
All subjects are on regular observation and follow-up at a 
pediatric endocrinology outpatient clinic.
3 |  DISCUSSION
Congenital HH is a very rare genetic disorder characterized 
by complete or partial lack of pubertal development therefore 
leading to infertility associated to complete or partial absence 
of GnRH-mediated release of LH and FSH in the setting of 
otherwise normal anterior pituitary anatomy and function.1,3-5
According to recent knowledge, only one-third of the HH 
cases have an inheritable basis. However, the autosomal re-
cessive mode of inheritance accounts just for 30% of these 
familial cases.4 Genetic defects of GNRHR, GNRH1, KISS1R, 
and TAC3/TACR3 are implicated in HH. Mutations in TAC3/
TACR3, as seen in this family, have been reported in 5% cases 
of HH inherited by the autosomal recessive mode.1,3-6
TAC3 encodes Neurokinin B (also known as tachykinin 
neurokinin-3), a neurotransmitter, which is primarily ex-
pressed by hypothalamic neurons. This neuropeptide is the 
ligand for the neurokinin-3 receptor, which is encoded by 
TACR3 gene.7
The mutations of both genes are associated with a 
Neurokinin B malfunction. Precise mechanisms by which 
these mutations cause gonadotropin deficiency and HH are 
not yet clear; however, these mutations have a critical role in 
sexual maturation.6,8
The mutation 824G>A (p.Trp275*) in TACR3 is one of 
the mutations described in this family and produces a stop 
codon in the 5th transmembrane segment (p.Trp275Stop) of 
NK3R, resulting in an absent or disrupted protein product 
with a pathological effect.6,9 The second identified muta-
tion in this family (c.689G>A (p.Arg230His)) involves the 
alteration of a nucleotide that is conserved through species 
(Arg230) producing a variant currently classified of uncer-
tain significance due to lack of clinical information and func-
tional studies.10
The genetic study of this family favors the pathogenicity 
of the second variant (p. Arg230His), since all three indi-
viduals with the compound heterozigosity present with the 
clinical diagnosis and all three familial members that are het-
erozygous for a single mutation (subjects II-1, II-2 and III-
2) have normal pubertal development, regardless of gender 
(complete genotype-phenotype correlation).
The treatment of nHH is primarily focused on hormone 
replacement with sex steroids (testosterone, estrogen, and 
progesterone) in order to promote normal sex hormones’ lev-
els, the development of secondary sex characteristics, and a 
eugonadal state. GnRH or gonadotropin therapies are the best 
options for the infertility treatment.11-13
After discontinuation of sex steroid therapy, patients with 
TAC3/TACR3 mutations sometimes show partial sexual mat-
uration and often experience partial or complete recovery of 
their reproductive axis with spontaneous fertility achieved in 
some cases.1,2,5,7,14-16 At 21 years of age, the affected male 
reached Tanner stage IV-V after 9 months of puberty induc-
tion with testosterone and human chorionic gonadotrophin, 
whereas his 17-year-old sister is still on transdermal steroid 
replacement with Tanner stage III and no menarche. A lon-
ger follow-up of this family is required to understand whether 
sexual maturation and fertility will be achieved in all three 
siblings.
This familial case of congenital HH seems to be a unique 
disease model in which a new described association of 
two heterozygous TACR3 mutations (p.Arg230His and 
p.Trp275*) appears to be responsible for a clinical trait.
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Further genetic testing considering these compound het-
erozygous mutations may therefore play a key role in the 
diagnosis and prognosis of nHH, opening barriers to novel 
disease classification and unraveling new paths for gene ther-
apy in the future.
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